Learning from History: Making Biosimilars a Reality - Genetic ...

More documents

Recommendations

Info

Innovation required in both technical developmentand clinical developmentKey challengesTime &Investment• Significant expense (USD 100 - 250m)• Long time to develop (7-8 years)TechnicalDevelopment• Achieving “highly similar” to match originatormolecule profile• Matching final dosage form of originatorClinicalDevelopment• Use of novel endpoints and populations to confirmbiosimilarity (not de novo safety/efficacy)• Clinical trial design to support extrapolation acrossindications, interchangeability & commercial success10 | Genetic Engineering & Biotechnology News Webinar on Biosimilars, November 2012
Biosimilars must be systematically engineered tomatch the reference productReferenceproductClinical2. Confirmationof biosimilarity1. Target directeddevelopmentTarget rangeDrug productdevelopmentPK/PDPreclinicalPurification processdevelopmentProcessdevelopmentBiologicalcharacterizationBioprocess developmentRecombinant cell line developmentAnalyticsPhysicochemicalcharacterizationLeveraging biological variability11 | Genetic Engineering & Biotechnology News Webinar on Biosimilars, September 2012
Page 1 and 2: Learning from History: Making Biosi
Page 5 and 6: OverviewWhy biosimilars?QbD and the
Page 7 and 8: © Sandoz 2012By 2016, 7 of the top
Page 9: Biologics are more complex than sma
Page 13 and 14: QbD biosimilar product specificatio
Page 15 and 16: Fingerprint mAbs/Fusion proteins as
Page 19 and 20: Exaggerated expectations for Biosim
Page 21 and 22: SPR real time binding assay much mo
Page 25 and 26: UK example:Biosimilars expand acces
Page 27 and 28: Analytical Characterization of Biop
Page 29 and 30: Amino acids ->peptides->proteins->P
Page 31 and 32: Tissue PlasminogenActivator [tPA]:
Page 33 and 34: Role of appropriate due diligence s
Page 35 and 36: Underscoring the need for appropria
Page 37 and 38: Biologics Price Competition and Inn
Page 39 and 40: Nature Reviews Drug Discovery, 2012
Page 41 and 42: FDA desire for specific innovations
Page 43 and 44: Differences in Sites of Fucosylatio
Page 45 and 46: ETD to analyze formation of isoAsp
Page 47 and 48: High order structures ofvery comple
Page 49 and 50: Ability to assign structural change
Page 51 and 52: Nature Reviews Drug Discovery, 2012
Page 53 and 54: size exclusionchromatography (SEC)a
Page 57 and 58: Are the Molecules Similaror are The
Page 59 and 60: Focus of GuidanceQualityScientificS
Page 61 and 62:
A Stepwise Approach to Demonstratin
Page 63 and 64:
Our Focus: PK & Immunogenicity•Ou
Page 65 and 66:
Typical ELISA Method for PK Determi
Page 67 and 68:
Best Practice for Side by SideCompa
Page 69 and 70:
Progression of Immunogenicity Testi
Page 71 and 72:
Antibodies Can Cross React with Mul
Page 73 and 74:
Why Conduct an Immunogenicity Asses
Page 75 and 76:
Antibody Characterization: Binding
Page 77 and 78:
Cell Based Assays:Product Release a
Page 79 and 80:
Target Cell and Neutralizing Antibo
Page 81 and 82:
Corporate OverviewIllinoisWIL Resea
Page 83 and 84:
Thank YouMarie Rock, Ph.D.
Page 85 and 86:
Learning from History: Making Biosi
Page 87 and 88:
Page 89:
show all

Learning from History: Making Biosimilars a Reality - Genetic ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?